EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic Drug Monitoring of GS-441524 in Cats with Feline Infectious Peritonitis: Pharmacokinetic Variability and Implications for Dose Optimization

Stephen W Cooke iD, Rachael Hammond iD, Danièlle A Gunn-Moore iD

Pathogens · 06.03.2026 · 15 (3) · 291

DOI: 10.3390/pathogens15030291 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, online erschienen am 06.03.2026. Verfasst von Stephen W Cooke und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Microsampling Laboratory Ltd., Oxfordshire OX10 7EX, UK. Hauptthemen laut MEDLINE: Feline Infectious Peritonitis, Antiviral Agents, Drug Monitoring, Adenosine Monophosphate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Microsampling Laboratory Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Remdesivir (REM) and its parent drug, GS-441524 (GS-44), are used to treat cats with feline infectious peritonitis (FIP), resulting in a survival rate of circa 85% (range 77–96%). Cats suffering from FIP exhibit complex and variable clinical presentations, which will cause concurrent variations in the pharmacokinetics (PK) of GS-44. In turn, this will vary the ability of target cells (monocytes and tissue macrophages) to absorb GS-44 in sufficient quantities to achieve optimal antiviral efficacy, resulting in full recovery. Sparse data exists to guide treatment regimens optimized for every presentation of FIP. Therapeutic Drug Monitoring (TDM) measured the GS-44 concentration in 728 blood samples from 263 cats undergoing treatment and generated 173 PK graphs. These identified individuals varied in their ability to absorb GS-44, leading to sub-optimal (11%) and supra-optimal (12%) dose-normalized plasma concentrations. Dosage alterations were suggested to guide subsequent dosages to ensure optimum GS-44 concentrations for individual cats (the clinical outcome report will be published separately). Proposed TDM target values are: area under the concentration vs. time curve (AUC), at least 220 µM·h, time per day that plasma concentration exceeds 3 µM, at least 23 h, time per day plasma concentration exceeds 10 µM, and at least 9 h.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Feline Infectious PeritonitisAntiviral AgentsDrug MonitoringAdenosine MonophosphateAnimalsCatsAdenosine

Stichwörter der Autor:innen

FIPGS-441524HPLCTherapeutic Drug Monitoringcatdosagefeline infectious peritonitisplasma concentrationremdesivirtreatment

Substanzen

Antiviral AgentsGS-441524Adenosine MonophosphateAdenosine

Autor:innen und Institutionen

  • The Microsampling Laboratory Ltd., Oxfordshire OX10 7EX, UK.
  • Royal (Dick) School of Veterinary Science, The University of Edinburgh, Edinburgh EH25 9RG, UK.

ORCID-Profile: Stephen W Cooke, Rachael Hammond, Danièlle A Gunn-Moore

Förderung

  • The Microsampling Laboratory Ltd.

Zitieren

APA

Cooke, S. W., Hammond, R., & Gunn-Moore, D. A. (2026). Therapeutic Drug Monitoring of GS-441524 in Cats with Feline Infectious Peritonitis: Pharmacokinetic Variability and Implications for Dose Optimization. Pathogens, 15(3), 291. https://doi.org/10.3390/pathogens15030291

Vancouver

Cooke SW, Hammond R, Gunn-Moore DA. Therapeutic Drug Monitoring of GS-441524 in Cats with Feline Infectious Peritonitis: Pharmacokinetic Variability and Implications for Dose Optimization. Pathogens. 2026;15(3):291. doi:10.3390/pathogens15030291

BibTeX
@article{Cooke2026,
  author = {Cooke, Stephen W and Hammond, Rachael and Gunn-Moore, Danièlle A},
  title = {Therapeutic Drug Monitoring of GS-441524 in Cats with Feline Infectious Peritonitis: Pharmacokinetic Variability and Implications for Dose Optimization},
  journal = {Pathogens},
  year = {2026},
  volume = {15},
  number = {3},
  pages = {291},
  doi = {10.3390/pathogens15030291}
}
Kostenlos starten →